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Results Nineteen patients were enrolled (normal, n = 6; 
moderate, n = 7; severe, n = 6). Renal impairment was 
associated with an increased mean dose-normalized area 
under the concentration–time curve (ratios for moderate/
normal and severe/normal: 1.49; 90 % confidence interval 
[CI] 0.9, 2.45). CrCl and renal function correlated posi-
tively, with a numerically small slope (0.0184; 90 % CI 
−0.00254, 0.0394). A simulated dose reduction to eribulin 
1.1 mg/m2 in patients with moderate or severe renal impair-
ment achieved the same exposure as 1.4 mg/m2 in those 
with normal renal function. All groups had similar toxicity 
profiles, with no unexpected adverse events.
Conclusions Renal impairment decreased eribulin clear-
ance and increased exposure. Pharmacokinetic evaluation 
supports an eribulin dose reduction to 1.1 mg/m2 in patients 
with moderate or severe renal impairment.
ClinicalTrials.gov Identifier NCT01418677.
Keywords Renal function · Renal impairment · Cancer 
patients · Eribulin · Pharmacokinetics
Introduction
Eribulin mesylate (eribulin; also known as eribulin 
mesylate; Eisai Inc., NJ, USA) is a synthetic analogue of 
the biologically active macrocyclic portion of halichondrin 
B, a natural product isolated from the marine sponge Hali-
chondria okadai [1]. Halichondrin B is a large polyether 
macrolide that exerts potent anticancer effects in cell-based 
and animal models of cancer [1–3]. In the USA, eribulin 
is indicated for the treatment of patients with metastatic 
breast cancer who have previously received at least 2 chem-
otherapeutic regimens for the treatment of metastatic dis-
ease. Prior therapy should have included an anthracycline 
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eribulin mesylate pharmacokinetics following a single dose 
in adults with advanced solid tumors.
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erate impairment (creatinine clearance [CrCl] 30–50 mL/
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and a taxane in either the adjuvant or metastatic setting. 
The recommended dose is eribulin mesylate 1.4 mg/m2 
(equivalent to 1.23 mg/m2 eribulin, expressed as free base), 
administered intravenously over 2–5 min on days 1 and 8 
of a 21-day cycle [4, 5].
In humans, eribulin (free base) has a rapid distribution 
phase followed by a prolonged elimination phase, with a 
mean terminal half-life (t½) of approximately 40 h [6, 7]. 
It has a large volume of distribution at steady state (Vss 
43–114 L/m2) [4, 6] and low plasma total clearance (CLtot 
1.16–2.42 L/h/m2) [7, 8]. Metabolism accounts for a minor 
portion of eribulin clearance [9]. Following administration 
of 14C-eribulin mesylate 2 mg to patients, unchanged parent 
compound accounted for almost all of the eribulin-derived 
radioactivity [9]. Hepatic impairment affects the disposition 
of eribulin by decreasing clearance and prolonging elimi-
nation half-life, resulting in increased exposure to eribulin 
[10]. Consequently, the US eribulin package insert recom-
mends that the eribulin mesylate dose be reduced from 1.4 
to 1.1 mg/m2 in patients with mild (Child–Pugh A) hepatic 
impairment or to 0.7 mg/m2 in patients with moderate 
(Child–Pugh B) hepatic impairment [4]. Renal elimina-
tion is a minor route for eribulin excretion, with less than 
10 % of the drug excreted unchanged in urine; the major-
ity is excreted unchanged in feces [9]. Although it cannot 
be directly measured, biliary excretion may also contribute 
substantially to eribulin clearance.
In toxicokinetic studies, no significant accumulation of 
eribulin was observed with weekly administration (admin-
istered once per week for 3 weeks) [11]. Eribulin exposure 
following the second or third weekly dose of the first cycle 
is comparable to that achieved following a single dose [4]. 
Exposure is dose-related at doses of 0.25–4.0 mg/m2 [6, 
7]. Population pharmacokinetic (PK) analyses showed that 
eribulin clearance is affected by levels of serum albumin, 
alkaline phosphatase, and bilirubin [12]. The effects of age, 
sex, race, and concomitant medications (cytochrome P450 
inhibitors and inducers) on clearance were not significant. 
After normalizing for body weight, creatinine clearance 
(CrCl) had no effect on eribulin clearance.
Based on the PK characteristics of eribulin, the pri-
mary assessment in this study was conducted on eribulin 
in plasma and followed the principles outlined in the US 
Food and Drug Administration (FDA) Renal Impairment 
Study Guidance for Industry [13]. The primary objective 
was to study the influence of moderate and severe renal 
impairment on the PK of eribulin following a single intra-
venous (i.v.) administration of eribulin mesylate to patients 
with cancer. The secondary objective was to explore the 
safety and tolerability of eribulin mesylate when adminis-
tered repeatedly in patients with moderate and severe renal 
impairment, as well as in those with normal renal function.
Materials and methods
Study design
This was a multicenter, open-label, nonrandomized, 
sequential-cohort trial in patients with advanced or meta-
static solid tumors who were no longer responding to 
available therapy. Patients at 6 centers received eribu-
lin mesylate administered as a single i.v. infusion over 
2–5 min on days 1 and 8 of a 21-day cycle. The dose 
was determined by each patient’s renal function (normal 
renal function: CrCl ≥80 mL/min; moderate renal impair-
ment: CrCl 30–50 mL/min; severe renal impairment: CrCl 
15–29 mL/min). CrCl rates were estimated by the Cock-
croft–Gault formula. Patients with normal renal func-
tion were matched to those with moderate or severe renal 
impairment with regard to sex, age, height, and weight, to 
the maximum extent possible. To assure selection of a suit-
able eribulin mesylate dose for patients with renal impair-
ment, the study initially recruited and dosed only those 
with moderate renal impairment, who received eribulin 
mesylate 1.4 mg/m2 on cycle 1 day 1, and then 1.1 mg/
m2 on cycle 1 day 8 and for all subsequent doses. Patients 
with severe renal impairment received eribulin mesylate 
0.7 mg/m2, and those with normal renal function received 
1.4 mg/m2 on days 1 and 8 of each 21-day cycle. Patients 
continued to receive the study drug on days 1 and 8 of 
each cycle until their study participation ended. To evalu-
ate the need for dose adjustment for patients with severe 
renal impairment, eribulin exposure was compared with 
predicted exposure based on a population PK model. Insti-
tutional review board approvals were obtained from all 
clinical sites prior to study initiation.
Ethical approval
All procedures performed in this study involving human 
participants were in accordance with the ethical standards 
of the institutional and/or national research board and with 
the principles of the 2008 Declaration of Helsinki.
Patients
To be eligible to participate in the trial, men and women 
had to meet the following key inclusion criteria: aged 
18 years or older at the time of informed consent; his-
tologically or cytologically confirmed advanced solid 
tumors that had progressed following standard therapy or 
for which no standard therapy existed; renal function in 
1 of 3 categories: normal (CrCl ≥80 mL/min), moderate 
impairment (CrCl 30–50 mL/min), or severe impairment 
(CrCl 15–29 mL/min); resolution of all chemotherapy- or 
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radiation-related toxicities to grade 1 or lower; Eastern 
Cooperative Oncology Group Performance Status score of 
0, 1, or 2; adequate liver function as evidenced by biliru-
bin levels of up to 1.5× the upper limit of normal (ULN) 
and levels of alkaline phosphatase, alanine aminotrans-
ferase, and aspartate aminotransferase up to 3× ULN; and 
adequate bone marrow function as evidenced by absolute 
neutrophil count of at least 1.5 × 109/L, hemoglobin con-
centration of at least 10.0 g/dL and platelet count of at least 
100 × 109/L. All patients provided written informed con-
sent and were willing and able to comply with all aspects 
of the protocol. Exclusion criteria included: hypersensitiv-
ity to halichondrin B or its derivatives; neuropathy greater 
than grade 2; radiation therapy to more than 30 % of bone 
marrow; organ allografts that required immunosuppression; 
clinically significant illness requiring medical treatment 
during the 8 weeks, or a clinically significant infection 
during the 4 weeks preceding the first dose; corrected QT 
(QTc) interval longer than 500 ms; positive test result for 
human immunodeficiency virus, hepatitis A, B, or C; sig-
nificant cardiovascular impairment such as a history of con-
gestive heart failure greater than grade 2, unstable angina 
or myocardial infarction within the past 6 months, or seri-
ous cardiac arrhythmia; brain or subdural metastases; and 
presence of meningeal carcinomatosis.
Pharmacokinetic assessments
Blood samples for eribulin PK analysis were collected on 
cycle 1 day 1, predose (time 0) and at the following post-
dose time points: 15 and 30 min, and 1, 2, 4, 6, 10, 24, 
48, 72, 96, 120, 144, and 168 h. Additional blood sam-
ples were collected 30 min and 24 h postdose to determine 
the unbound fraction of total plasma drug concentration. 
Plasma concentrations of eribulin were estimated using 
noncompartmental analysis to determine: area under the 
concentration–time curve from time zero extrapolated to 
infinity (AUC0–inf), AUC from time zero to last measur-
able time point (AUC0–t), maximum observed concentra-
tion (Cmax), t½, CLtot, Vss, and unbound fraction of plasma 
drug concentration. Plasma concentrations of eribulin were 
quantified by liquid chromatography with tandem mass 
spectrometry using a previously validated assay [14]; the 
lower limit of quantification was 0.2 ng/mL.
Safety assessments
All adverse events (AEs) and serious AEs (SAEs) were 
recorded using the Common Terminology Criteria for 
Adverse Events (CTCAE) v4.0 grades (for both increasing 
and decreasing severity). Safety assessments also included: 
monitoring and recording of all concomitant medications; 
regular monitoring of hematology, blood chemistry, and 
urine analysis values; periodic assessment of vital signs 
and electrocardiograms; and physical examinations. All 
hematology, blood chemistry (including pregnancy test, if 
applicable), and urinalysis samples were obtained before 
study-drug administration. Data from the safety assess-
ments were reviewed before dispensing of the study drug at 
the beginning of each cycle. Treatment-emergent, markedly 
abnormal laboratory values were defined as an increase 
from baseline to a postbaseline CTCAE grade 2 or higher 
(grade 3 or higher for phosphate).
Efficacy assessments
Patients were evaluated for efficacy by serial computerized 
tomography scans of the chest, abdomen, and pelvis, every 
2 cycles (6 weeks). Best overall response was based on the 
tumor response evaluation as determined by the investi-
gator, according to Response Evaluation Criteria in Solid 
Tumors 1.1 [15]. Responses of complete response (CR) and 
partial response (PR) must have been confirmed at least 
4 weeks following the first response.
Statistical assessments
To compare eribulin exposure in patients with renal impair-
ment with that in patients with normal renal function, 
exposure (AUC0–inf and Cmax values) was dose-normalized 
to account for different doses tested in each treatment 
group. The relationship between the individual eribulin 
PK parameters and estimated renal function (CrCl) was 
analyzed using a linear regression model, which was suf-
ficient to describe the data. The log-transformed PK param-
eters (dose-normalized AUC0–inf, AUC0–t, Cmax, and CLtot) 
were the dependent variables, while CrCl was the inde-
pendent variable. Individual CrCls were estimated by the 
Cockcroft–Gault formula using serum creatinine data from 
screening (day −21 to day −1), or from baseline visits if 
the screening value was missing. Safety variables were 
analyzed using descriptive summary statistics and changes 
from baseline were evaluated by renal function group. 




Nineteen patients were enrolled and treated with eribu-
lin mesylate (normal renal function, n = 6; moderate 
renal impairment, n = 7; severe renal impairment, n = 6) 
between October 2011 and July 2013 (data cut-off). 
Patient demographic and other baseline characteristics are 
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presented in Table 1. Overall, the majority of patients were 
white (63.2 %), female (63.2 %), and 70 years of age or 
older (52.6 %). More than half of the patients in the mod-
erate and severe renal impairment groups were females 
who were age 69 and older. Based on screening or base-
line serum creatinine values, the mean estimated CrCl 
was 89.6 mL/min (±standard deviation [SD] 9.1) for the 
normal renal function group, 42.6 mL/min (±SD 6.3) for 
the moderate renal impairment group, and 24.4 mL/min 
(±SD 4.9) for the severe renal impairment group. No sin-
gle tumor type was predominant among the three groups 
(Table 1).
Table 1  Study population baseline characteristics
BSA body surface area, CrCl creatinine clearance, ECOG Eastern Cooperative Oncology Group, SD standard deviation
Parameter Normal renal function  
(n = 6)
Moderate renal impairment 
(n = 7)




Eribulin mesylate dose 1.4 mg/m2 1.4 mg/m2 0.7 mg/m2
Women, n 4 6 2 12
Age, years
 Median 63.5 73.0 73.5 70.0
 Range 33–72 34–82 56–81 33–82
Race, n
 White 4 6 2 12
 Black/African–American 2 1 4 7
Weight, kg
 Mean (SD) 78.2 (20.2) 77.0 (16.4) 67.1 (9.3) 74.3 (15.9)
 Range 47.4–97.3 45.9–101.2 54.7–81.2 45.9–101.2
Height, cm
 Mean (SD) 166.7 (12.4) 159.8 (9.5) 170.9 (7.3) 165.4 (10.5)
 Range 158.0–191.0 149.4–178.6 163.3–182.0 149.4–191.0
BSA, m2
 Mean (SD) 1.860 (0.264) 1.796 (0.192) 1.797 (0.069) 1.816 (0.184)
 Range 1.48–2.21 1.45–2.03 1.71–1.90 1.45–2.21
Tumor type
 Breast 2 2 0 4
 Cervix uteri 0 1 0 1
 Esophagus 1 0 1 2
 Mouth 1 0 0 1
 Lung/bronchus 2 1 1 4
 Ovary 0 2 1 3
 Prostate gland 0 0 1 1
 Testis 0 1 0 1
 Urinary bladder 0 0 2 2
Number of previous anticancer regimens, n
 1 1 0 1 2
 2 0 1 1 2
 3 0 0 1 1
 ≥4 5 6 3 14
ECOG status, n
 0 1 0 2 3
 1 5 7 4 16
CrCl, mL/min
 Mean (SD) 89.6 (9.1) 42.6 (6.3) 24.4 (4.9) 51.7 (28.4)
 Range 81.4–107.2 29.8–48.1 16.7–29.7 16.7–107.2
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Plasma concentration–time profiles 
and pharmacokinetic parameters
All 19 enrolled patients had evaluable PK data and were 
included in the analysis. Figure 1 shows the mean ± SD 
eribulin plasma concentration–time profiles by renal 
impairment group. Eribulin exhibited multiphasic disposi-
tion following i.v. drug administration. There was a rapid 
distribution phase followed by a prolonged elimination 
phase. At the same 1.4 mg/m2 dose, patients with moder-
ate renal impairment had higher eribulin plasma concentra-
tions than those with normal renal function. Patients with 
severe renal impairment received a lower dose (0.7 mg/m2) 
and had a lower eribulin plasma concentration profile than 
those with normal renal function. The variability in eribu-
lin exposure was comparable across groups; the interpatient 
variability (%CV) for AUC0–inf was 49, 59, and 39 % for 
patients with normal renal function, moderate renal impair-
ment, or severe renal impairment, respectively.
Table 2 shows eribulin PK parameters by renal function 
group. Renal impairment had no effect on eribulin protein 
binding. The fraction of unbound drug was 15.2 and 18.3 % 
in patients with normal renal function at 30 min and 24 h 
postdose, respectively, and ranged from 13.4 to 18.7 % in 
patients with moderate and severe renal impairment for the 
2 collection time points. Renal impairment decreased eribu-
lin clearance. CLtot in patients with moderate and severe 
renal impairment was 2.07 and 2.01 L/h, respectively, com-
pared with 3.13 L/h in those with normal renal function. 
Eribulin t½ was similar in all 3 groups (43.4 h in patients 
with normal renal function compared with 43.9 h in those 
with moderate renal impairment, and 38.7 h in those with 
severe renal impairment).
Pharmacokinetic statistical analysis
Renal impairment increased both the AUC0–inf and Cmax of 
eribulin. Moderate or severe renal impairment increased 
mean dose-normalized AUC0–inf 1.49-fold (90 % CI 0.9, 
2.45) compared with normal renal function. Mean dose-
normalized eribulin AUC0–inf was similar in patients with 
moderate or severe impairment (ratio estimate, 1.00 [90 % 
CI 0.61, 1.65]). The increase in dose-normalized Cmax 
was 1.31-fold (90 % CI 0.84, 2.05) for moderate renal 
impairment and 2.02-fold (90 % CI 1.27, 3.21) for severe 
renal impairment compared with normal renal function. 
The increase in dose-normalized Cmax in the severe renal 
impairment group was influenced by the Cmax observed in 
one patient (612 ng/mL), which was approximately three-
fold higher than Cmax values for the other five patients in 
this group (range 162–197 ng/mL).
The magnitude of the slope for the linear correlation 
between eribulin CLtot and renal function (CrCl) was small 
and the corresponding 90 % CI included zero (0.0184, CI 
−0.0025, 0.0394) (Fig. 2). The negative slopes for the lin-
ear correlations between AUC and Cmax and CrCl were also 






















































Normal (n = 6)
Moderate impairment (n = 7)
Severe impairment (n = 6)
Normal (n = 6)
Moderate impairment (n = 7)
Severe impairment (n = 6)
(b)(a)
Fig. 1  a Linear and b semi-log plots of mean (±standard deviation) 
eribulin plasma concentration versus time following a single intrave-
nous administration of eribulin mesylate 1.4 mg/m2 to patients with 
normal renal function, 1.4 mg/m2 to patients with moderate renal 
impairment, and 0.7 mg/m2 to patients with severe renal impairment. 
Data shown as mean ± standard deviation
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Safety
The number of doses of eribulin mesylate received ranged 
from 2 to 18, with a median of 2.5, 5.0, and 5.0 doses for 
patients with normal renal function, moderate renal impair-
ment, or severe renal impairment, respectively. No find-
ings suggest any change in the established safety profile of 
eribulin mesylate. No patients discontinued study treatment 
owing to a treatment-emergent AE (TEAE) as the primary 
reason.
All 19 patients experienced at least 1 TEAE (defined as 
an AE that started after study drug administration on day 
1 or re-emerged or worsened during treatment), with 17 
patients (89.5 %) having AEs reported as treatment-related 
by the investigator. The most frequently reported TEAEs 
(occurring in 3 or more patients in any group) were 
fatigue, nausea, alopecia, decreased appetite, leukopenia 
and neutropenia (Table 3). TEAEs were similar across 
groups, with the exception of an increased incidence of 
alopecia, fatigue, nausea, and decreased appetite in the 
group with moderate renal impairment and an increased 
incidence of leukopenia and neutropenia in patients with 
normal renal function.
Overall, grade 3 TEAEs occurred in five patients 
(26.3 %) and grade 4 TEAEs occurred in seven patients 
(36.8 %). Grade 3 events (highest grade) occurred in two 
patients with moderate renal impairment, in two patients 
with normal renal function, and in one patient with severe 
renal impairment. Grade 4 events occurred in two patients 
with moderate renal impairment, in one patient with severe 
renal impairment, and in four patients with normal renal 
function. There were no substantial differences among 
the renal groups for the incidence of grade 3 TEAEs, but 
owing to neutropenia and neutropenia-associated TEAEs, 
the incidence of grade 4 TEAEs was greater in those with 
normal renal function. The most frequently reported grade 
3 and grade 4 TEAEs were neutropenia and neutropenia-
associated TEAEs, which occurred primarily in patients 
with normal renal function who were administered eribulin 
mesylate 1.4 mg/m2 throughout the study.
Nine patients experienced treatment-emergent SAEs. No 
type (preferred term) of SAE occurred in more than one 
patient. SAEs reported as treatment-related occurred in two 
patients: dehydration and acute renal failure in one patient 
with severe renal impairment, and febrile neutropenia in 
one patient with normal renal function. One of the SAEs 
led to death: a patient with severe renal impairment died 
31 days after a single dose of study drug, with the cause 
of death reported as dyspnea. The dyspnea started before 
study drug initiation and increased in severity to grade 2 
on day 8; it was most likely related to disease progression. 
A second death occurred: one patient in the normal renal 
group died owing to progressive disease on day 27, 20 days 
after the last dose of study drug.
Table 2  Mean (SD) pharmacokinetic parameters following single intravenous administration of eribulin in patients with normal renal function 
and patients with moderate or severe renal impairment on day 1
AUC0–inf area under the plasma concentration–time curve from time 0 to infinity, AUC0–t area under the plasma concentration–time curve from 
time 0 to the last measurable concentration, CLtot total clearance, Cmax maximum observed plasma concentration, SD standard deviation, t½ ter-
minal half-life, Vss steady-state volume of distribution
a n = 6
Parametera Normal renal function (n = 6) Moderate renal impairment (n = 7) Severe renal impairment (n = 6)
Eribulin mesylate dose 1.4 mg/m2 1.4 mg/m2 0.7 mg/m2
Dose normalized, mean (SD)
 Cmax, ng/mL/mg 109 (50.4) 140 (51.6) 236 (176)
 AUC0–inf, ng h/mL/mg 408 (224) 595 (299)
a 575 (232)
 AUC0–t, ng h/mL/mg 391 (227) 532 (245) 546 (203)
Actual values, mean (SD)
 Cmax, ng/mL 242 (82.7) 306 (95.3) 254 (176)
 AUC0–inf, ng h/mL 912 (434) 1320 (779)
a 624 (230)
 AUC0–t, ng h/mL 868 (433) 1200 (621) 593 (199)
 t½, h 43.4 (15.3) 43.9 (10.9)
a 38.7 (12.5)
 CLtot, L/h 3.13 (1.65) 2.07 (1.03)
a 2.01 (0.875)
 Vss, L 144 (73.7) 86.5 (32.7)
a 66.6 (26.8)
Fraction unbound, %, mean (SD)
 30 min postdose 15.2 (4.75) 13.8 (3.50) 16.2 (3.35)
 24 h postdose 18.3 (7.05) 13.4 (7.72)a 18.7 (11.7)
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Two patients (1 in each of the moderate and severe renal 
impairment groups) had QTc prolongation; the first patient 
had at least 1 postbaseline value of >480 ms during treat-
ment. The second patient had at least 1 postbaseline value 
of >480 and >500 ms. The readings were considered abnor-
mal but not clinically significant. Both patients had base-
line readings that were also considered abnormal but not 
clinically significant (484 and 474 ms, respectively). No 
clinically significant changes were observed in any other 
safety evaluations, including vital signs.
Efficacy
The best overall response was stable disease, observed in 
ten patients. Of these, four patients were in the moderate 
renal impairment group (1 testicular, 1 ovarian, and 2 breast 
cancers), four patients were in the severe renal impairment 
group (1 ovarian, 1 prostate, and 2 bladder cancers), and 
two patients were in the normal renal function group (1 
breast and 1 oral cancer). None of the patients experienced 
a CR or PR. Nine patients experienced progression of dis-
ease at their disease assessment.
Discussion
The recommended starting dose of eribulin mesylate in 
the USA for patients with moderate renal impairment 
(CrCl 30–50 mL/min) is 1.1 mg/m2 (equivalent to eribulin 
0.97 mg/m2, expressed as free base) administered intra-
venously for 2–5 min on days 1 and 8 of a 21-day cycle 
[4]. The current European prescribing information does 
not recommend any specific dose adjustments for patients 
with mild or moderate renal impairment, but advises that 
patients with severely impaired renal function (CrCl 
<40 mL/min) may need a dose reduction [5]. In the cur-
rent study, mean eribulin exposure in patients with mod-
erate renal impairment was 63 % higher than the mean 
predicted exposure in patients with normal renal function. 
Anticipating a greater effect of severe renal impairment on 
eribulin exposure, the eribulin mesylate dose was decreased 
to 0.7 mg/m2 for patients with severe renal impairment to 
minimize potential risks.
Only a few blood samples were collected to assess 
unbound eribulin concentration because eribulin has low 

































































































Slope estimate (SE): 0.0184 (0.00988)
90% CI: –0.00254, 0.0394
Slope estimate (SE): –0.0097 (0.00378)
90% CI: –0.0177, –0.00176
Slope estimate (SE): –0.00642 (0.00379)
90% CI: –0.0144, 0.00157
Slope estimate (SE): –0.00638 (0.00400)

















Fig. 2  Individual eribulin plasma clearance (a) and log-transformed 
dose-normalized Cmax (b), AUC(0–t) (c) and AUC(0–inf) (d) versus 
creatinine clearance. AUC area under the concentration–time curve, 
AUC0–t AUC from time 0 to the last measurable concentration, 
AUC(0–inf) area under the concentration–time curve from time zero 
extrapolated to infinity, CI confidence interval, CLtot total clearance, 
Cmax maximum plasma concentration, SE standard error
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Table 3  Most frequent treatment-emergent adverse events
Patients with 2 or more TEAEs in the same system organ class (or with the same preferred term) are counted only once for that system organ 
class (or preferred term)
TEAEs treatment-emergent adverse events
System organ class (preferred term) Normal renal function (n = 6) Moderate renal impairment (n = 7) Severe renal impairment (n = 6)
Eribulin mesylate dose 1.4 mg/m2 1.4 mg/m2 0.7 mg/m2
TEAEs occurring in at least 3 patients in a group
 Alopecia 0 4 0
  Grade 1 or 2 0 4 0
  Grade 3 or 4 0 0 0
 Decreased appetite 0 3 1
  Grade 1 or 2 0 3 1
  Grade 3 or 4 0 0 0
 Fatigue 1 7 3
  Grade 1 or 2 1 6 3
  Grade 3 or 4 0 1 0
 Leukopenia 3 1 0
  Grade 1 or 2 1 0 0
  Grade 3 or 4 2 1 0
 Neutropenia 3 1 0
  Grade 1 or 2 0 0 0
  Grade 3 or 4 3 1 0
 Nausea 1 4 1
  Grade 1 or 2 1 4 1
  Grade 3 or 4 0 0 0
TEAEs occurring in at least 2 patients in a group
 Anemia 0 2 0
  Grade 1 or 2 0 2 0
  Grade 3 or 4 0 0 0
 Blood creatinine increased 0 2 0
  Grade 1 or 2 0 2 0
  Grade 3 or 4 0 0 0
 Constipation 0 2 2
  Grade 1 or 2 0 2 2
  Grade 3 or 4 0 0 0
 Dysgeusia 0 2 0
  Grade 1 or 2 0 2 0
  Grade 3 or 4 0 0 0
 Hypertension 0 2 0
  Grade 1 or 2 0 2 0
  Grade 3 or 4 0 0 0
 Edema, peripheral 1 0 2
  Grade 1 or 2 1 0 2
  Grade 3 or 4 0 0 0
 Pyrexia 1 2 0
  Grade 1 or 2 1 2 0
  Grade 3 or 4 0 0 0
 Vomiting 0 2 1
  Grade 1 or 2 0 2 1
  Grade 3 or 4 0 0 0
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expected for a drug with less than 80 % protein binding, 
eribulin data did not show any pattern of changes in the 
free eribulin fraction with increasing renal impairment. 
Therefore, all PK assessments were performed using total 
eribulin concentration.
In line with previous phase I studies in patients with nor-
mal renal function, the plasma concentration–time profile 
of eribulin exhibited a rapid distribution phase followed 
by a slow elimination phase in all 3 patient groups [6, 7]. 
However, renal impairment did decrease eribulin clearance. 
Mean CLtot was approximately 33 % lower in patients with 
moderate or severe renal impairment than in those with 
normal renal function. AUC and Cmax were also higher in 
patients with moderate or severe renal impairment than in 
those with normal renal function. However, the dose-nor-
malized eribulin Cmax in patients with normal renal func-
tion (109 mg/mL) was lower than reported in 2 previous 
phase I studies (that reported ranges of 163–202 mg/mL 
[for doses of 0.25–1.40 mg/m2] [6] and 138–209 mg/mL 
[for doses of 0.25–4.0 mg/m2] [7]). In the current study, 
the dose-normalized Cmax for patients with moderate renal 
impairment (140 mg/mL) was within the range previously 
reported in patients with normal renal function. When 
excluding the patient with the unusually high Cmax (612 ng/
mL), the Cmax values for patients with severe renal impair-
ment (162–197 ng/mL) were also within these ranges.
Given the limited urinary elimination of eribulin, the 
reduction in eribulin CLtot is probably due to indirect 
effects of renal impairment on hepatic function or biliary 
excretion. Indeed, renal impairment may affect the nonre-
nal elimination of drugs that are primarily metabolised or 
secreted in bile by inhibiting pathways of hepatic and gut 
drug metabolism. The retention of waste products caused 
by renal impairment may impact on drug transporters such 
as P-glycoprotein (P-gp; of which eribulin is a substrate 
[17]), thereby impairing the biliary excretion of the drugs 
they transport. This is supported by preclinical experiments, 
which demonstrated that chronic renal failure in rats is asso-
ciated with a decrease in intestinal P-gp protein expression 
and function, which could explain the increased bioavail-
ability of drugs observed with chronic renal failure [18].
The linear correlation between the degree of renal 
impairment (CrCl) and eribulin clearance (CLtot) showed a 
positive trend, but the correlation was not significant and 
the slope was numerically small. Similarly, linear regres-
sion of CrCl and dose-normalized AUC and Cmax showed 
negative trends with nonsignificant correlations, indicating 
an increase in eribulin exposure with impairment of renal 
function (i.e., lower CrCl). Lack of statistical significance 
in linear correlations between renal impairment and eribu-
lin PK parameters reflects a relatively small effect of renal 
impairment on eribulin disposition, and a lack of incremen-
tal effect of severity of renal impairment on eribulin dis-
position (i.e., moderate and severe impairment have similar 
effects on eribulin AUC and Cmax).
Eribulin was generally well tolerated in all groups; this 
is consistent with data from a previous phase I trial in 
patients with renal dysfunction (20–40 mL/min, Cockroft–
Gault, not requiring dialysis) in which eribulin was well 
tolerated at doses of 0.7, 1.0, and 1.4 mg/m2 i.v. on days 
1 and 8 of a 21-day cycle [19, 20]. The toxicities experi-
enced by patients in all groups were consistent with the 
known side-effect profile of eribulin. No unexpected AEs 
developed during treatment in patients with decreased renal 
function. Although the patient numbers in each group were 
too small to draw conclusions about specific events, there 
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Fig. 3  Eribulin exposure in patients with normal renal function at a dose of 1.4 mg/m2 and predicted eribulin exposure at a dose of 1.1 mg/m2 in 
patients with moderate or severe renal impairment. AUC area under the curve, CI confidence interval
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Compared with eribulin exposure following a dose of 
1.4 mg/m2 in patients with normal renal function, exposure 
to eribulin in patients with severe renal impairment follow-
ing a dose of 0.7 mg/m2 was approximately 30 % lower, and 
exposure in patients with moderate impairment following a 
dose of 1.4 mg/m2 was approximately 50 % higher. Calcula-
tions were done to evaluate an intermediate dose that would 
achieve eribulin exposure in patients with renal impairment 
that was comparable to that following the recommended dose 
of 1.4 mg/m2 in patients with normal renal function. Eribu-
lin exposure was calculated for a dose of 1.1 mg/m2 based 
on estimated CLtot in patients with moderate or severe impair-
ment. Since this study enrolled a slightly greater proportion of 
older females in the moderate and severe renal insufficiency 
groups, it is unknown if this may have contributed to reduced 
eribulin dosing in the setting of renal impairment. A popula-
tion PK model [12] was used to predict individual exposure 
(AUC) in 195 patients with normal renal function dosed with 
eribulin mesylate 1.4 mg/m2 from 7 phase I studies and 1 
phase II study. As shown in Fig. 3, a dose of 1.1 mg/m2 in 
patients with moderate or severe renal impairment results in 
a comparable eribulin exposure to that observed in patients 
with normal renal function dosed with eribulin mesylate 
1.4 mg/m2 in this and previous studies. In line with this, the 
FDA has recently recommended to reduce the starting dose of 
eribulin mesylate to 1.1 mg/m2 in patients with moderate or 
severe renal impairment (CrCl 15–49 mL/min) [21].
In conclusion, renal impairment affects the PK of 
eribulin. Based on these findings, it is recommended that 
patients with moderate or severe renal impairment receive a 
reduced dose of 1.1 mg/m2 eribulin mesylate on days 1 and 
8 of a 21-day cycle.
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